GlassScriptPhysician profile
Antonio Ortiz
NPI 1871213538
$1,722.92
in general payments reported to CMS, 2019-2025
15 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $85.94 · 2023: $455 · 2024: $834 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.76 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $533.36 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $267.32 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $237.67 | 2022-2024 | Mounjaro |
| Amgen INC. | $223.08 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $186.50 | 2022-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.00 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.13 | 2022-2023 | Xifaxan |
| Pfizer INC. | $30.55 | 2023-2025 | |
| Glaxosmithkline, LLC. | $29.51 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abiomed | $26.43 | 2024 | Impella |
| Abbvie INC. | $26.39 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.60 | 2023 | Gattex |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.09 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $15.29 | 2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.